Home FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
 

Keywords :   


FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

2015-04-29 05:21:48| drugdiscoveryonline Home Page

Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, recently announced that the U.S

Tags: type primary treatment drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
10.05Alabama second state to ban lab-grown meat
10.05Senators request more aggressive approach on HPAI countermeasures
10.05Lidl raises pay to match Aldi in battle for staff
10.05Faisal Islam: Economy is getting better but people may not notice
10.05Sulfate-Free Foamable Solid Cleanser Patented by Johnson & Johnson
10.05Farm Progress America, May 10, 2024
10.05Farm Progress America, May 10, 2024
10.05Bank 'optimistic' as it edges closer to summer cut
More »